Cancer Drugs Likely Losers In Reformed Medicare Rules
As ever, cancer drugs were much in the news last week, with Onyx Pharmaceuticals Inc.'s stock taking a 33 percent hit after the firm disclosed a likely delay in getting its renal cancer drug approved - and the drugs are going to make headlines even more often in the months ahead. The stories may be even sadder for approved drugs.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST